Lilly anticipates prasugrel decision today
Eli Lilly and Co. will learn a lot about its future today. The U.S. Food and Drug Administration is scheduled to rule on Lilly’s new blood-thinner prasugrel today after a nine-month review of clinical trial data. If approved, prasugrel will go on the market immediately under the name Effient. Prasugrel is the first big test […]